tetano
Editor, Senior Moderator
J Thromb Thrombolysis
. 2021 Jun 26.
doi: 10.1007/s11239-021-02514-3. Online ahead of print.
Pragmatic study of a thromboprophylaxis algorithm in critically ill patients with SARS-COV-2 infection
Maurizio Fattorutto[SUP] 1 [/SUP], Yves Bouckaert[SUP] 2 [/SUP], Jonathan Brauner[SUP] 3 [/SUP], Stéphane Franck[SUP] 2 [/SUP], Fabrice Bouton[SUP] 2 [/SUP], Danielle Heuse[SUP] 2 [/SUP], Charlotte Bouckaert[SUP] 4 [/SUP], Arnaud Bruyneel[SUP] 2 5 [/SUP]
Affiliations
Abstract
The optimal thromboprophylactic strategy for patients affected by Coronavirus disease 2019 (COVID-19) has been debated among experts. This study evaluated the safety and efficacy of a thromboprophylaxis algorithm. This was a retrospective, single-center study in critically ill patients admitted to the intensive care unit (University affiliated Hospital) for acute respiratory failure due to Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2). From March 16 to April 9, 2020, thromboprophylaxis was adjusted according to weight (control group, n = 19) and after this date, thromboprophylaxis depended on an algorithm based on thrombotic and hemorrhagic risk factors (protocol group, n = 13). With regard to safety (number of major bleeding events and blood transfusions), the groups were not significantly different. With regard to efficacy, the number of thrombotic events decreased from 37 to 0%, p = 0.025 after implementation of the algorithm. Also, peak fibrinogen dropped from 8.6 (7.2-9.3) to 6.5 (4.6-8.4) g/L, p = 0.041 and D-dimers from 2194 (1464-3763) to 1486 (900-2582) ng/mL, p = 0.0001. In addition, length of stay declined from 19 (10-31) to 5 (3-19) days, p = 0.009. In conclusion, a tailored thromboprophylaxis algorithm (risk stratification based on clinical parameters and biological markers) reduce thrombotic phenomena in critically ill COVID-19 patients without increasing major bleeding.
Keywords: Anticoagulation; COVID-19; Hypercoagulability; SARS-CoV-2; Thrombosis.
. 2021 Jun 26.
doi: 10.1007/s11239-021-02514-3. Online ahead of print.
Pragmatic study of a thromboprophylaxis algorithm in critically ill patients with SARS-COV-2 infection
Maurizio Fattorutto[SUP] 1 [/SUP], Yves Bouckaert[SUP] 2 [/SUP], Jonathan Brauner[SUP] 3 [/SUP], Stéphane Franck[SUP] 2 [/SUP], Fabrice Bouton[SUP] 2 [/SUP], Danielle Heuse[SUP] 2 [/SUP], Charlotte Bouckaert[SUP] 4 [/SUP], Arnaud Bruyneel[SUP] 2 5 [/SUP]
Affiliations
- PMID: 34173169
- DOI: 10.1007/s11239-021-02514-3
Abstract
The optimal thromboprophylactic strategy for patients affected by Coronavirus disease 2019 (COVID-19) has been debated among experts. This study evaluated the safety and efficacy of a thromboprophylaxis algorithm. This was a retrospective, single-center study in critically ill patients admitted to the intensive care unit (University affiliated Hospital) for acute respiratory failure due to Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2). From March 16 to April 9, 2020, thromboprophylaxis was adjusted according to weight (control group, n = 19) and after this date, thromboprophylaxis depended on an algorithm based on thrombotic and hemorrhagic risk factors (protocol group, n = 13). With regard to safety (number of major bleeding events and blood transfusions), the groups were not significantly different. With regard to efficacy, the number of thrombotic events decreased from 37 to 0%, p = 0.025 after implementation of the algorithm. Also, peak fibrinogen dropped from 8.6 (7.2-9.3) to 6.5 (4.6-8.4) g/L, p = 0.041 and D-dimers from 2194 (1464-3763) to 1486 (900-2582) ng/mL, p = 0.0001. In addition, length of stay declined from 19 (10-31) to 5 (3-19) days, p = 0.009. In conclusion, a tailored thromboprophylaxis algorithm (risk stratification based on clinical parameters and biological markers) reduce thrombotic phenomena in critically ill COVID-19 patients without increasing major bleeding.
Keywords: Anticoagulation; COVID-19; Hypercoagulability; SARS-CoV-2; Thrombosis.